News
ProStrakan Partners with Aptalis for Rectiv in the US
9th January 2012
Click Here to download release
FDA Approves Shared REMS for all TIRF Pain Treatments
30th December 2011
Click Here to download release
ProStrakan Receives FDA Approval for Rectiv for the Treatment of Moderate to Severe Pain Associated with Chronic Anal Fissures
22nd June 2011
Click here to download release
Recommended Acquisition of ProStrakan Group plc by Kyowa Hakko Kirin Co., Ltd. Scheme of Arrangement becomes effective
21st April 2011
Click here to download release
Notice of Cancellation of Listing from the Official List
21st April 2011
Click here to download release
Recommended cash acquisition of ProStrakan Group plc by Kyowa Hakko Kirin Co., Ltd. Court sanction of Scheme and confirmation of Capital Reduction
20th April 2011
Click here to download release
NOTICE OF TEMPORARY SUSPENSION OF LISTING FROM THE OFFICIAL LIST
19th April 2011
Click here to download release
Result of Resolutions Passed at General Meeting of the Company
7th January 2011
Click here to download release
ProStrakan and Paladin Labs Announce New Strategic Relationship and Financing Agreement
16th December 2010
Click here to download release
Notification of Date of Interim Management Statement
11th November 2010
Click here to download release
Dealing by Directors and Persons Discharging Managerial Responsibilities
8th September 2010
Click here to download release
Block Listing Six Monthly Review - Sharesave Plan 06.09.10
6th September 2010
Click here to download release
Block Listing Six Monthly Return - SIL Option Scheme 06.09.10
6th September 2010
Click here to download release
Block Listing Six Monthly Return - plc Exec Option Plan
6th September 2010
Click here to download release
Block Listing Six Monthly Return - Performance Share Plan 06.09.10
6th September 2010
Click here to download release
Interim Results for the Six Months Ended 30 June 2010
19th August 2010
Click here to download press release
ProStrakan Receives Complete Response for Rectogesic from FDA
1st April 2010
Click here to download release
Preliminary Results for the Year Ended 31 December 2009
ProStrakan Announces Canadian Regulatory Filing of Abstral
Allan Watson Receives Investor Relations Award
ProStrakan Announces FDA Acceptance of US Submission of Cellegesic™ (nitroglycerin) 0.4% Ointment
ProStrakan Announces FDA Acceptance of Abstral Filing
Dealing by Directors and Persons Discharging Managerial Responsibilities
ProStrakan Partners with Endo for Fortigel (FORTESTA) in the US
26th August 2009
Click here to download press release
Interim Results for the Six Months Ended 30 June 2009
20th August 2009
Click here to download press release
ProStrakan Announces Upcoming Launch of Abstral in France
30th June 2009
Click here to download press release
ProStrakan Announces Publication of Notice of Allowance for Sancuso US Patent
25th June 2009
Click here to download press release
Annual information update for period 23 May 2008 up to and including 15 May 2009
15th May 2009
Results of Resolutions Passed at Annual General Meeting
20th May 2009
ProStrakan Announces US Submission of Fortigel (testosterone) 2% Gel
5th May 2009
ProStrakan Announces US Co-Promotion Agreement for Oncology Support Product, Gelclair
18th March 2009
Abstral Receives Marketing Approval in France and Spain
2nd March 2009
Preliminary Results for Year Ended 31 December 2008
18th March 2009
ProStrakan Announces Further Outlicensing Deals in Globalisation of Sancuso
9th February 2009
Change of announcement date for 2008 Preliminary Results
